Have a feature idea you'd love to see implemented?
Let us know!
VRPX Virpax Pharmaceuticals Inc
Price (delayed)
$0.349
Market cap
$1.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.8
Enterprise value
$1.69M
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval using its three patented drug
Highlights
The EPS has grown by 35% from the previous quarter and by 25% YoY
Virpax Pharmaceuticals's net income has increased by 23% from the previous quarter and by 2.8% YoY
The equity has plunged by 132% YoY but it has grown by 27% from the previous quarter
Virpax Pharmaceuticals's quick ratio has plunged by 99% YoY and by 97% from the previous quarter
Key stats
What are the main financial stats of VRPX
Market
Valuations
Earnings
Shares outstanding
4.89M
Market cap
$1.71M
Enterprise value
$1.69M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$13.24M
EBIT
-$13.14M
EBITDA
-$13.14M
Free cash flow
-$16.85M
Per share
Balance sheet
Liquidity
EPS
-$8.8
EPS diluted
-$8.8
Free cash flow per share
-$3.62
Book value per share
-$0.42
Revenue per share
$0
TBVPS
$0.07
Total assets
$304,162
Total liabilities
$2.36M
Debt
$0
Equity
-$2.05M
Working capital
-$2.05M
Debt to equity
0
Current ratio
0.13
Quick ratio
0.01
Net debt/EBITDA
0
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-338.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRPX stock price
How has the Virpax Pharmaceuticals stock price performed over time
Intraday
-1.99%
1 week
-12.09%
1 month
-12.75%
1 year
-86.93%
YTD
-8.13%
QTD
-8.13%
Financial performance
How have Virpax Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.37M
Net income
-$13.24M
Gross margin
N/A
Net margin
N/A
VRPX's operating income is up by 24% since the previous quarter and by 5% year-on-year
Virpax Pharmaceuticals's net income has increased by 23% from the previous quarter and by 2.8% YoY
Growth
What is Virpax Pharmaceuticals's growth rate over time
Valuation
What is Virpax Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 35% from the previous quarter and by 25% YoY
The equity has plunged by 132% YoY but it has grown by 27% from the previous quarter
Efficiency
How efficient is Virpax Pharmaceuticals business performance
The ROA has contracted by 39% from the previous quarter
Dividends
What is VRPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRPX.
Financial health
How did Virpax Pharmaceuticals financials performed over time
The total assets is 87% less than the total liabilities
Virpax Pharmaceuticals's quick ratio has plunged by 99% YoY and by 97% from the previous quarter
The total assets has plunged by 98% YoY and by 88% from the previous quarter
Virpax Pharmaceuticals's debt is 100% more than its equity
The equity has plunged by 132% YoY but it has grown by 27% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.